Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder

American Journal of Managed Care

Volumn 11, Issue SUPPL. 4, 2005, Pages

  Varadharajan, Sujata ^a   Jumadilova, Zhanna ^a   Girase, Prafulla ^a   Ollendorf, Daniel A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXYBUTYNIN; TOLTERODINE;

ADULT; AGE DISTRIBUTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG RELEASE; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESOURCE ALLOCATION; STATISTICAL SIGNIFICANCE;

AGED; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INSURANCE COVERAGE; MALE; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; UNITED STATES; URINARY INCONTINENCE;

EID: 22544470277     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Getsios D, Caro JJ, Ishak KJ, et al. Oxybutynin extended release and tolterodine immediate release. Clin Drug Invest. 2004;24:8-88.
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327-336.
3. Gross A, Gates C. Transdermal oxybutynin in overactive bladder. Hospital Pharmacist. 2004;11:467-468.
4. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61:1123-1128.
5. Ginsberg DA. Overactive bladder: past, present and future. Available at: http:/www.urologytimes.com/urologytimes/article/articleDetail.jspid=140399. Accessed January 19, 2005
6. Lai HH, Tim BB, Rodney AA. Selecting a medical therapy for overactive bladder. Rev Urol. 2002;4(suppl 4):S28-S37.
7. Chancellor MB. New frontiers in the treatment of overactive bladder and incontinence. Rev Urol. 2002;4(suppl 4):S50-S56.
8. MacDiarmid S. New antimuscarinic therapy for the treatment of mixed incontinence. Rev Urol. 2003;5(suppl 8):S18-S25.
9. Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily oxybutynin. BJU Int. 2000;85:793-798.
10. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology. 2001;57:414-421.
11. Noe L, Becker R, Williamson T, Chen D. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm. 2002;8:343-352.
12. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol. 1998;81:801-810.
13. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;(50 suppl 6A):90-96;discussion 97-99.
14. Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol. 2001;165:1452-1456.
15. Millard R, Tuttle J, Moore K, et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol. 1999;161:1551-1555.
16. Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br J Urol. 1998;81:42-48.
17. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001;76:358-363.
18. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
19. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
20. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care. 2000;6(11 suppl):S574-S579.